Rogers Corp (ROG)

60.11
0.12 0.20
NYSE : Technology
Prev Close 59.99
Open 60.42
Day Low/High 60.42 / 60.42
52 Wk Low/High 41.92 / 69.26
Volume 381.00
Avg Volume 132.70K
Exchange NYSE
Shares Outstanding 18.04M
Market Cap 1.10B
EPS 2.50
P/E Ratio 28.16
Div & Yield N.A. (N.A)

Latest News

Phase III Efficacy Results Of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis

Phase III Efficacy Results Of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis

Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive...

Phase III Study Showed Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People With A Specific Type Of Lung Cancer Live Significantly Longer Compared To Chemotherapy

Phase III Study Showed Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People With A Specific Type Of Lung Cancer Live Significantly Longer Compared To Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results for TECENTRIQ from the Phase III study, OAK.

Rogers Corporation To Participate In Drexel Hamilton Telecom, Media & Technology Conference

Rogers Corporation To Participate In Drexel Hamilton Telecom, Media & Technology Conference

Rogers Corporation (NYSE:ROG) will be participating in the Drexel Hamilton Telecom, Media & Technology Conference on Wednesday, September 7, 2016 in New York, NY.

Not-So-Jolly Rogers Thanks to Quant Downgrade, Bearish Chart

Not-So-Jolly Rogers Thanks to Quant Downgrade, Bearish Chart

The stock gaped to the downside Tuesday and has continued lower today.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ACM, ACTS, BID, CC, COH, COKE, DSCI, EGRX, FNV, NWS, SHO, SSNC Downgrades: AMBC, HHC, HLF, LXFR, ROG, TCP Initiations: APLE, CNXR, EKSO, GNL, HLTH, LIND Read on to get TheStreet Quant Ratings' detailed report:

Rogers Corporation To Relocate Global Headquarters To Arizona

Rogers Corporation To Relocate Global Headquarters To Arizona

Rogers Corporation (NYSE:ROG), a global leader in engineered materials solutions, announced today it will relocate its global headquarters from Rogers, Connecticut to Chandler, Arizona.

Rogers Corporation Reports Second Quarter 2016 Results

Rogers Corporation Reports Second Quarter 2016 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2016 second quarter.

Roche Introduces Virtual Reality Theater At AACC 2016 Clinical Lab Expo To Give Lab Professionals Firsthand Glimpse Of Connected Lab Of The Future

Roche Introduces Virtual Reality Theater At AACC 2016 Clinical Lab Expo To Give Lab Professionals Firsthand Glimpse Of Connected Lab Of The Future

Automated workflows and integrated IT solutions that connect chemistry, coagulation and molecular diagnostics promise to deliver results to physicians faster, more reliably

Roche Launches New Target Enrichment Systems For Genetic And Translational Research

Roche Launches New Target Enrichment Systems For Genetic And Translational Research

HEAT-Seq Target Enrichment Systems help provide fast, accurate detection of human genetic variants

Rogers Corporation Invites You To Join Its 2016 Second Quarter Earnings Conference Call

Rogers Corporation Invites You To Join Its 2016 Second Quarter Earnings Conference Call

Rogers Corporation (NYSE: ROG) plans to announce results for its 2016 second quarter after the close of trading on Monday, August 8, 2016.

Roche Receives CLIA Waiver For Cobas® Influenza A/B & RSV Test For The Cobas® Liat®

Roche Receives CLIA Waiver For Cobas® Influenza A/B & RSV Test For The Cobas® Liat®

The first CLIA-waived, real-time PCR test that differentiates flu and RSV in 20 minutes is available now for use in physician offices and urgent care settings

Genentech Provides Update On Phase III Study Of Gazyva® In People With Previously Untreated Diffuse Large B-Cell Lymphoma

Genentech Provides Update On Phase III Study Of Gazyva® In People With Previously Untreated Diffuse Large B-Cell Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III GOYA study evaluating Gazyva ® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated...

Roche Receives FDA Approval For Use Of SurePath Preservative Fluid With Cobas HPV Test For Cervical Cancer Screening

Roche Receives FDA Approval For Use Of SurePath Preservative Fluid With Cobas HPV Test For Cervical Cancer Screening

Roche HPV test is first to be approved for use with the SurePath Preservative Fluid gynecologic cell collection medium commonly used for Pap tests

FDA Approves Genentech's Xolair® (omalizumab) For Allergic Asthma In Children

FDA Approves Genentech's Xolair® (omalizumab) For Allergic Asthma In Children

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Rogers Corporation To Participate In CJS Securities, Inc. Sixteenth Annual

Rogers Corporation To Participate In CJS Securities, Inc. Sixteenth Annual "New Ideas" Summer Conference

Rogers Corporation (NYSE:ROG) will be participating in the Sixteenth Annual CJS Securities "New Ideas" Summer Conference on Tuesday, July 12, 2016 in White Plains, NY.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

FDA Grants Priority Review For Genentech's OCREVUS™ (ocrelizumab) Biologics License Application

FDA Grants Priority Review For Genentech's OCREVUS™ (ocrelizumab) Biologics License Application

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.

Sanofi's Likely Sweetener for Medivation Panned

Sanofi's Likely Sweetener for Medivation Panned

The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.

Roche Receives FDA Clearance For Its Procalcitonin (PCT) Assay To Help Clinicians Effectively Assess Sepsis Risk And Manage Sepsis Patients

Roche Receives FDA Clearance For Its Procalcitonin (PCT) Assay To Help Clinicians Effectively Assess Sepsis Risk And Manage Sepsis Patients

First IVD company to provide a fully integrated solution for PCT testing with Elecsys BRAHMS PCT

Phase III Study Shows Genentech's Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

Phase III Study Shows Genentech's Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra ® (tocilizumab) in people with giant cell...

Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors In People With Previously Untreated Advanced Bladder Cancer

Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors In People With Previously Untreated Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in a Phase II study, IMvigor 210, TECENTRIQ™ (atezolizumab) shrank tumors (objective response rate, ORR) in 24 percent (n=28)...

FDA Grants First Liquid Biopsy Approval To The Roche Cobas® EGFR Mutation Test V2

FDA Grants First Liquid Biopsy Approval To The Roche Cobas® EGFR Mutation Test V2

Test can be used with either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapy